Perplexity AI Predicts Whether Moderna Stock Can Make Investors Rich in 2026

A single trial readout just doubled a company’s market value in one session.

Perplexity AI predicts the rerating continues, and the price prediction places Moderna at $180 to $240 by the end of 2026 with a $210 bullish base case.The catalyst is Intismeran, the personalized mRNA cancer vaccine.

Perplexity calls it the dominant valuation driver going forward. The Phase 3 INTerpath-001 melanoma trial met both primary endpoints.

Recurrence-free survival and distant-metastasis-free survival both cleared alongside Keytruda.That is the first late-stage validation of Moderna’s oncology platform.